Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02HWR
|
|||
| Former ID |
DIB014778
|
|||
| Drug Name |
PV-1019
|
|||
| Synonyms |
Checkpoint kinase 2 inhibitor (cancer), Provid Pharmaceuticals; Chk2 inhibitor (cancer), Provid Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Company |
Provid Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase Chk2 (RAD53) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Cell cycle | |||
| p53 signaling pathway | ||||
| HTLV-I infection | ||||
| Pathway Interaction Database | ATM pathway | |||
| FOXM1 transcription factor network | ||||
| p53 pathway | ||||
| PLK3 signaling events | ||||
| Reactome | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
| G2/M DNA damage checkpoint | ||||
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | ||||
| WikiPathways | DNA Damage Response | |||
| ATM Signaling Pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Prostate Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Integrated Cancer pathway | ||||
| Cell Cycle | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.